The invasion and spread of cancer cells to other parts of the body, known as metastasis, is a principal cause of death in patients diagnosed with breast cancer. Although patients with early stage, small, breast tumours have an excellent short term prognosis, more than 15 to 20 per cent of them will eventually develop distant metastases, and die from the disease. Vascular invasion — through lymphatic and blood vessels — is the major route for cancer spreading to regional lymph nodes and to the rest of the body.

Dr Stewart Martin, Professor Ian Ellis and their colleagues at The University of Nottingham, and worldwide, are combining a number of approaches in a dynamic effort to improve our understanding of cell behaviour in breast cancer.

Discovering how these cells operate is vital in improving diagnosis and treatment for the cancer patient in the longer term, and in identifying therapeutic targets.

Already the results of their work have been excellent — with findings in relation to the spread of cancer through the lymphatic vessels prompting a much larger study funded by Cancer Research UK.

A research student within the Nottingham team, Rabab Mohammed, showed recently that specific factors that regulate the growth of blood and lymphatic vessels can identify a subset of tumours which have a high probability of recurring or spreading.

The team subsequently identified the crucial importance of assessing both the level of blood and lymph vessel invasion by cancer cells at the earliest stages of detection. It has, until recently, been very difficult to distinguish between the two. With advances in immunohistochemical techniques, blood vessels can today be reliably identified and differentiated from lymphatics. Currently clinical approaches for the assessment of vascular invasion are insufficiently robust and can result in a failure to detect some lesions accurately, or fail to differentiate adequately between blood and lymph vessels. The Nottingham team has shown — using tumour sections from 177 patients — that 96 per cent of vascular invasion in primary invasive breast cancer is predominantly of the lymph vessels. This is significant.

It is important that this finding is verified in a larger cohort of patients. The researchers are now working to accomplish this, through funding recently obtained from Cancer Research UK, using specimens from more than a thousand women with early stage breast cancer. Results from this study will also allow them to determine whether Lymphatic Vascular Invasion can be incorporated into an improved prognostic index for early stage breast cancer.

This work is being combined with gene expression studies, with bioinformatic approaches and using in vitro (cells in culture) models to identify novel therapeutic targets.  It is being conducted in collaboration with a number of groups, industrial and academic, from both the UK and overseas.

                                  - Ends -

References:

1. Mohammed RAA, Green A, El-Sheikh S, Paish EC, Ellis IO, Martin SG (2007) Prognostic significance of vascular endothelial cell growth factors -A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis. British Journal of Cancer 96, 1092-1100.

2. Mohammed RAA, Martin SG, El-Sheikh S, Ellis IO (2007) Improved methods of detection of lymphovascular invasion demonstrate that it is the predominant method of vascular invasion in breast cancer and has important clinical consequences. American Journal of Surgical Pathology 31(12):1825-33

Additional References of Relevance:

Mohammed RAA, Ellis IO, Elsheikh S, Paish EC, Martin SG. (2008) Lymphatic and angiogenic characteristics in breast cancer: morphometric analysis and prognostic implications. Breast Cancer Research and Treatment. Feb 22. [Epub ahead of print]

Mohammed RAA, Ellis IO, Lee AHS, Martin SG (2008) Vascular invasion in breast cancer; an overview of recent prognostic developments and molecular pathophysiological mechanisms. Histopathology (in press).

Notes to editors: The University of Nottingham is ranked in the UK’s Top 10 and the World’s Top 70 universities by the Shanghai Jiao Tong (SJTU) and Times Higher (THE) World University Rankings.

It provides innovative and top quality teaching, undertakes world-changing research, and attracts talented staff and students from 150 nations. Described by The Times as Britain’s “only truly global university”, it has invested continuously in award-winning campuses in the United Kingdom, China and Malaysia. Twice since 2003 its research and teaching academics have won Nobel Prizes. The University has won the Queen’s Award for Enterprise in both 2006 (International Trade) and 2007 (Innovation — School of Pharmacy).

Its students are much in demand from ‘blue-chip’ employers. Winners of Students in Free Enterprise for four years in succession, and current holder of UK Graduate of the Year, they are accomplished artists, scientists, engineers, entrepreneurs, innovators and fundraisers. Nottingham graduates consistently excel in business, the media, the arts and sport. Undergraduate and postgraduate degree completion rates are amongst the highest in the United Kingdom.

Story Credits

More information is available from Dr Stewart Martin, Division of Clinical Oncology, University of Nottingham, on +44 (0)115 8231847, .(JavaScript must be enabled to view this email address); Professor Ian Ellis, on +44 (0)115 9691169 ext 46875, .(JavaScript must be enabled to view this email address).

Jonathan Ray
Jonathan Ray - Director of Communications
Email: .(JavaScript must be enabled to view this email address)
Phone: +44 (0)115 9515765 Fax: +44 (0)115 9515733
Location: King’s Meadow Campus